Sign up for the Oncology Series
Frequency: Weekly
Issue Date: May 17, 2016
Immuno-Oncology Brief curates and provides you with informative articles from some of the most authoritative names in health information on the specialty of oncology focusing on immuno-oncology.
March 2016 (Discovery Medicine) Systematic Review – Full Text NK Cell-based Immunotherapies: Awakening the Innate Anti-cancer Response Natural killer (NK) cells are a critical component of innate immunity and are able to recognize and trigger cell death in tumors by detecting receptor expression abnormalities in transformed cells. Recent studies and clinical trials have highlighted that manipulation of NK cell activation can be used as an immunotherapy in cancer. This review provides an overview of potential immunotherapies that modulate NK cell responses against tumor metastases. |
January 2016 (HealthDay News) Article Nivolumab, Contact Immunotx Treats In-Transit Melanoma Nivolumab in combination with contact immunotherapy can successfully treat in-transit melanoma, according to two case reports published online Dec. 12 in the Journal of Dermatology. |
September 2015 (Medical News Today) Article Deadly melanoma discovery supports immunotherapy treatment for cancer The study involved obtaining 62 DM (desmoplastic melanoma) samples from the US and Australia, on which the researchers carried out next-generation, whole-genome and exome sequencing. The coding regions of the tumor’s genetic code were parsed “letter by letter” in order to find common mutations between the samples. |
